Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
272.59M | 278.30M | 309.20M | 298.54M | 267.12M | 186.89M | Gross Profit |
116.29M | 120.89M | 130.38M | 112.63M | 103.34M | 63.27M | EBIT |
-192.40M | -195.50M | -135.67M | -135.54M | -96.85M | -53.92M | EBITDA |
-140.77M | -152.53M | -99.00M | -418.98M | -89.91M | -39.51M | Net Income Common Stockholders |
-178.31M | -189.30M | -134.70M | -465.26M | -128.56M | -58.47M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
52.05M | 65.59M | 91.83M | 121.91M | 233.47M | 293.24M | Total Assets |
369.07M | 392.71M | 574.14M | 691.24M | 1.26B | 422.54M | Total Debt |
220.73M | 221.65M | 266.11M | 235.26M | 197.23M | 188.12M | Net Debt |
168.68M | 156.06M | 174.28M | 113.36M | -36.24M | -105.12M | Total Liabilities |
304.98M | 322.72M | 439.35M | 479.63M | 573.10M | 265.35M | Stockholders Equity |
64.09M | 69.99M | 134.80M | 211.60M | 690.70M | 157.19M |
Cash Flow | Free Cash Flow | ||||
-12.46M | -28.12M | -12.58M | -67.39M | -51.09M | -17.71M | Operating Cash Flow |
2.09M | -8.82M | -185.00K | -53.90M | -38.52M | -7.60M | Investing Cash Flow |
-17.90M | -18.75M | -10.06M | -15.76M | -506.69M | -10.12M | Financing Cash Flow |
-29.91M | 1.44M | -20.03M | -39.99M | 486.00M | 206.43M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
69 Neutral | $665.28M | 11.93 | 9.10% | 8.07% | -2.69% | 61.73% | |
61 Neutral | $14.60B | 5.95 | -4.32% | 3.69% | 2.76% | -30.49% | |
57 Neutral | $83.85M | ― | -16.55% | ― | -2.67% | 21.65% | |
53 Neutral | $117.40M | ― | 74.55% | 11.04% | -0.16% | 57.03% | |
49 Neutral | $57.70M | ― | -34.39% | ― | 18.20% | 50.14% | |
42 Neutral | $93.98M | ― | -135.48% | ― | -12.77% | 19.71% | |
41 Neutral | $40.10M | ― | -123.16% | ― | -15.07% | 33.40% |
On May 20, 2025, Cardlytics held its Annual Meeting where stockholders voted on several key proposals. The election of three board nominees, the ratification of Deloitte & Touche LLP as the independent auditor, the approval of the 2025 Equity Incentive Plan, and the advisory approval of executive compensation were all passed with majority votes. This meeting reflects the company’s ongoing governance and strategic planning efforts, potentially impacting its operational and financial strategies moving forward.
The most recent analyst rating on (CDLX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Cardlytics stock, see the CDLX Stock Forecast page.
Cardlytics, Inc. announced that Bank of America has issued a non-renewal notice for their existing agreements, set to expire on July 31, 2025, with operations continuing until January 27, 2026. Despite the non-renewal, Cardlytics believes the impact on its financial results will be minimal due to potential new arrangements with Bank of America and growth from other financial partners. Additionally, Cardlytics amended its loan facility with Banc of California, extending the maturity date to April 15, 2028, while maintaining $60 million in unused borrowings.